Myricetin-functionalized Prussian blue nanoparticles enable multi-modal therapy against methicillin-resistant Staphylococcus aureus and accelerate wound repair.

Traditional photothermal antibacterial therapy is limited by a narrow therapeutic window. Here, myricetin-functionalized Prussian blue analog nanoparticles (M@HPBA) are developed as a multimodal platform for methicillin-resistant Staphylococcus aureus (MRSA) infection and wound repair. Doping with cobalt, zinc, and copper enhances photothermal conversion and enzyme-mimetic activities. Under near-infrared irradiation, localized heating induces bacterial damage and triggers the controlled release of metal ions and myricetin. Released myricetin scavenges excess reactive oxygen species, alleviating oxidative stress and inflammation to promote healing. In vitro, M@HPBA with irradiation achieves high antibacterial efficiency against MRSA. In a murine wound infection model, this strategy markedly reduces bacterial burden and accelerates tissue regeneration, with a wound closure rate significantly higher than controls. Transcriptomic analysis reveals that M@HPBA regulates inflammatory and antioxidant pathways in MRSA-infected wounds, enhancing susceptibility to photothermal and ROS/metal ion killing. M@HPBA demonstrates broad-spectrum antibacterial activity and favorable biosafety. These findings establish a synergistic strategy integrating photothermal therapy, nanozyme catalysis, ion release, and antioxidant intervention, providing a translatable paradigm for precision antimicrobial therapy and infected wound management.